Form 4: Indaptus Therapeutics Director Hila Karah Acquires Stock Options
SEC Form 4
Director Hila Karah acquired stock options for 12,500 shares of Indaptus Therapeutics common stock on June 6, 2024.
Summary
- On June 6, 2024, Hila Karah, a director of Indaptus Therapeutics, Inc., acquired stock options for 12,500 shares.
- The exercise price of these options is $2.63 per share.
- The options vest on June 6, 2025, and expire on June 6, 2034.
- Following the transaction, Karah directly owns 12,500 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The director's acquisition could be interpreted as a positive signal, but it's not definitively bullish.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the stock option transaction. |
| 06/06/2025 | Date the stock options vest and become exercisable. |
| 06/06/2034 | Expiration date of the stock options. |
| 06/07/2024 | Date of signature on the Form 4. |
Keywords
stock options, Form 4, director, Indaptus Therapeutics, INDP, beneficial ownership, Hila Karah
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.